《蓝筹业绩》石药集团(01093.HK)首三季纯利35.18亿元人民币升25.1%
石药集团(01093.HK)公布截至今年9月底止首三季业绩,营业额192.15亿元人民币(下同),按年升14.6%。纯利35.18亿元,按年升25.1%;每股盈利29.43分。
期内,成药业务录得销售收入人民币157.13亿元,较去年同期增加17.4%。其中,神经系统疾病产品录得销售收入59.87亿元,增加9.6%。抗肿瘤产品录得销售收入47.17亿元,增加35.4%。,抗感染产品录得销售收入20.43亿元,减少13.8%。心血管疾病产品录得销售收入17.62亿元,增加68%。
维生素C原料业务於本期录得销售收入14.38亿元,较去年同期减少9.9%。受疫情影响,产品价格於第二季借势上涨,出口量创历史新高,惟随着出口市场需求放缓,产品价格於第三季相应回落。
抗生素原料业务於本期录得销售收入7.62亿元,较去年同期增加6.6%。期内市场需求平稳,产品价格略微回升。
集团今年以来申请专利129件,其中国内申请96件,国外申请33件;取得专利授权90件,其中国内授权75件,国外授权15件。未来三年,集团预计将上市新产品50余个,其中预计市场空间超过10亿元的重磅品种将不少於15个,可强力支持集团未来的高质量增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.